Niagen Bioscience, Inc. filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2026, disclosing a net loss of $1.173 million for the third quarter and net income of $6.108 million for the nine-month period.

Key Highlights

  • Nine-month net income: $6.108 million, compared to $13.250 million for the nine months ended September 30, 2025, according to the filing.
  • Q3 net loss: $(1.173) million for the three months ended September 30, 2026, versus net income of $4.578 million in the same period of 2025.
  • Nine-month net sales: $88.451 million, down from $95.584 million in the nine months ended September 30, 2025.
  • Gain on sale of operating segment: $4.781 million recognized during the nine months ended September 30, 2026, with no comparable figure in 2025.
  • Total assets: $108.694 million as of September 30, 2026, up from $106.406 million at December 31, 2025.
  • Common stock repurchase: 1,173 thousand shares repurchased for $5.121 million during the nine months ended September 30, 2026.
  • Shares outstanding: 79,196,903 as of October 30, 2026, per the filing cover page.

Niagen Bioscience Q3 and Year-to-Date Financial Results Through September 30, 2026

Niagen Bioscience, Inc. (NASDAQ:NAGE), headquartered in Los Angeles, California, reported a net loss of $1.173 million for the three months ended September 30, 2026, compared to net income of $4.578 million in the prior-year quarter, according to the filing. Net sales for the third quarter were $27.192 million, down from $33.986 million in the three months ended September 30, 2025. Gross profit for the quarter was $17.105 million versus $21.928 million a year earlier. Total operating expenses increased to $18.692 million in Q3 2026 from $17.692 million in Q3 2025, resulting in an operating loss of $1.587 million compared to operating income of $4.236 million in the prior-year period.

For the nine months ended September 30, 2026, the company reported net income of $6.108 million on net sales of $88.451 million. The filing disclosed a gain on sale of an operating segment of $4.781 million recognized during the nine-month period, which had no comparable amount in 2025. Nine-month operating income was $689 thousand, down from $12.193 million in the nine months ended September 30, 2025. Share-based compensation expense was $4.961 million for the nine-month period, compared to $4.319 million in the prior-year period.

As of September 30, 2026, the company reported total assets of $108.694 million and total liabilities of $25.620 million, leaving total stockholders' equity of $83.074 million. Cash and cash equivalents, including restricted cash of $152 thousand, stood at $69.509 million, up from $64.788 million at December 31, 2025. The accumulated deficit narrowed to $158.420 million from $164.528 million at December 31, 2025. During the nine months ended September 30, 2026, the company repurchased 1,173 thousand shares of common stock for $5.121 million, the filing stated.

What Was Disclosed

Niagen Bioscience, Inc. filed a Form 10-Q covering the three and nine months ended September 30, 2026, reporting a third-quarter net loss, lower year-to-date sales, a gain from an operating segment sale, a share repurchase program, and an improvement in stockholders' equity and cash position relative to year-end 2025.